Forest's preservative free heparin
FDA is asking the firm to recall all stocks of the drug remaining in retail channels because of potential safety concerns. The agency noted in a Sept. 11 reg letter that there is a "lack of assurance of sterility for lots of preservative-free sodium heparin injection currently in distribution." Forest said it discontinued marketing the DESI product after recall of one lot of the product in February due to contamination ("The Pink Sheet" March 17, T&G-7).
You may also be interested in...
Company is confident that data readout from pivotal trial could be ready before the end of 2020.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Cognoa said it will submit its AI-powered digital app for early detection of autism for de novo clearance with the US FDA. See what the company’s senior medical director of clinical adoption said about it here.